Partow Kebriaei, MD, discusses when the optimal time for transplant is in patients with acute lymphoblastic leukemia.

Panelists discuss how they collaborate with community oncology centers when receiving patient referrals for initial or ...

Dr Graff discusses the differences and similarities in managing adverse events associated with bispecific antibodies in ...

Dr Graff discusses her standard approach when initiating bispecific antibody treatment for patients, including whether to ...

Panelists discuss how to operationalize bispecific antibody (BsAb) therapy in community practices, summarizing the toxicities ...

Dr Graff discusses perceptions of the future for patients treated with bispecific antibodies for non-Hodgkin lymphoma, ...

Panelists discuss their perceptions of the future for patients treated with bispecific antibodies for non-Hodgkin lymphoma, ...

Dr Graff discusses the recommendations for identifying, evaluating, and managing neurological toxicities, including workup ...

Panelists discuss the recommendations for identifying, evaluating, and managing neurological toxicities, including workup and ...

Dr Graff discusses how to operationalize bispecific antibody (BsAb) therapy in community practices by summarizing the ...

Abdulraheem Yacoub, MD, discusses the adverse event profile of imetelstat when treating patients with myelodysplastic ...

The FDA has lifted clinical holds on trials of zevor-cel, satri-cel, and CT071, and trials will now resume in the US.